200 related articles for article (PubMed ID: 35695283)
1. Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
Todisco E; Gigli F; Ronchini C; Amato V; Sammassimo S; Pastano R; Parma G; Lapresa MT; Bertolini F; Corsini C; Gregato G; Poletti C; Pelicci PG; Alcalay M; Colombo N; Tarella C
Int J Cancer; 2022 Nov; 151(10):1791-1803. PubMed ID: 35695283
[TBL] [Abstract][Full Text] [Related]
2. Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experience.
Todisco E; Gigli F; Mantiero M; Sammassimo S; Pastano R; Ronchini C; Parma G; Lapresa MT; Iori AP; Bertolini F; Corsini C; Gregato G; Poletti C; Colombo N; Tarella C
Int J Cancer; 2021 Jan; 148(1):170-177. PubMed ID: 32856727
[TBL] [Abstract][Full Text] [Related]
3. Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V; Decroocq J; Garciaz S; Etienne G; Belhabri A; Bertoli S; Gastaud L; Simand C; Chantepie S; Uzunov M; Genthon A; Berthon C; Chiche E; Dumas PY; Vargaftig J; Salmeron G; Lemasle E; Tavernier E; Delage J; Loirat M; Morineau N; Blanc-Durand F; Pautier P; Vergé V; Auger N; Thomas M; Stefani L; Lepelley M; Boyer T; Thepot S; Gourin MP; Bourquard P; Duchmann M; Morice PM; Michallet M; Adès L; Fenaux P; Récher C; Dombret H; Pagès A; Marzac C; Leary A; Micol JB;
Clin Cancer Res; 2022 Dec; 28(23):5211-5220. PubMed ID: 36201165
[TBL] [Abstract][Full Text] [Related]
4. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
5. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
[TBL] [Abstract][Full Text] [Related]
7. Myeloid neoplasms post PARP inhibitors for ovarian cancer.
Caruso G; Gigli F; Parma G; Lapresa M; Derio S; Palaia I; Colombo N
Int J Gynecol Cancer; 2023 Apr; 33(4):598-606. PubMed ID: 36707087
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004).
Kim NK; Kim Y; Kim HS; Park SJ; Hwang DW; Lee SJ; Yoo JG; Chang SJ; Son JH; Kong TW; Kim J; Shim SH; Lee AJ; Suh DH; Lee YY
Cancer Med; 2023 Oct; 12(19):19449-19459. PubMed ID: 37768030
[TBL] [Abstract][Full Text] [Related]
9. Frequency of peripheral PD-1
Park J; Kim JC; Lee M; Lee J; Kim YN; Lee YJ; Kim S; Kim SW; Park SH; Lee JY
Br J Cancer; 2023 Nov; 129(11):1841-1851. PubMed ID: 37821637
[TBL] [Abstract][Full Text] [Related]
10. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
Tao M; Wu X
J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP; Lacchetti C; Ellis A; Maxian K; Banerjee S; Bookman M; Jones MB; Lee JM; Lheureux S; Liu JF; Moore KN; Muller C; Rodriguez P; Walsh C; Westin SN; Kohn EC
J Clin Oncol; 2020 Oct; 38(30):3468-3493. PubMed ID: 32790492
[TBL] [Abstract][Full Text] [Related]
12. Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
Cheng A; Rao Q; Liu Y; Huang C; Li J; Huo C; Lin Z; Lu H
Gynecol Oncol; 2022 Dec; 167(3):502-512. PubMed ID: 36270832
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis.
Peters ITA; Marchetti C; De Palma A; Giannarelli D; Carcagnì A; Scambia G; Fagotti A
Eur J Cancer; 2023 Jul; 187():77-86. PubMed ID: 37130463
[TBL] [Abstract][Full Text] [Related]
14. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
15. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
16. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
[TBL] [Abstract][Full Text] [Related]
17. Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
[TBL] [Abstract][Full Text] [Related]
18. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study.
Cerda VR; Lu D; Scott M; Kim KH; Rimel BJ; Kamrava M
Int J Gynecol Cancer; 2022 Feb; 32(2):153-158. PubMed ID: 34911701
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
Miller RE; El-Shakankery KH; Lee JY
J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
